Detecting functional changes with [(18)F]FAZA in a renal cell carcinoma mouse model following sunitinib therapy

BACKGROUND: The multitargeting tyrosine kinase inhibitor (TKI) sunitinib is currently the first-line drug therapy for metastasizing renal cell carcinoma (RCC). TKIs have profound effects on tumor angiogenesis, leading to modifications of the tumor microenvironment. The goal of this study was to dete...

Descripción completa

Detalles Bibliográficos
Autores principales: Chapman, David W, Jans, Hans-Sonke, Ma, Ivy, Mercer, John R, Wiebe, Leonard I, Wuest, Melinda, Moore, Ronald B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451188/
https://www.ncbi.nlm.nih.gov/pubmed/26116107
http://dx.doi.org/10.1186/s13550-014-0027-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451188/
https://www.ncbi.nlm.nih.gov/pubmed/26116107
http://dx.doi.org/10.1186/s13550-014-0027-5

Ejemplares similares